ZYVERSA THERAPEUTICS, INC. Operating Expenses
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Operating Expenses of $1.30 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-05-13
- ZYVERSA THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $1.30M, a 39.16% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $551.86K, a 57.11% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $20.75M, a 814.34% increase year-over-year.
- ZYVERSA THERAPEUTICS, INC. operating expenses for the quarter ending 2025-06-30 was $2.04M, a 25.78% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. operating expenses for fiscal 2025 was $25.49M, a 179.01% increase from fiscal 2024.
- ZYVERSA THERAPEUTICS, INC. operating expenses for fiscal 2024 was $9.14M, a 91.52% decline from fiscal 2023.
- ZYVERSA THERAPEUTICS, INC. operating expenses for fiscal 2023 was $107.75M.
| Period end | Operating Expenses 1 month | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 11 month | Operating Expenses 12 month |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1.30M 10-Q · filed 2026-05-13 | $1.86M derived: sum of 2 quarters · filed 2026-05-13 | $22.61M derived: sum of 3 quarters · filed 2026-05-13 | $24.65M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2025-12-31 | $551.86K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $21.30M derived: sum of 2 quarters · filed 2026-03-31 | $23.35M derived: sum of 3 quarters · filed 2026-03-31 | $25.49M 10-K · filed 2026-03-31 | ||
| 2025-09-30 | $20.75M 10-Q · filed 2025-11-19 | $22.80M derived: sum of 2 quarters · filed 2025-11-19 | $24.94M 10-Q · filed 2025-11-19 | $26.23M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2025-06-30 | $2.04M 10-Q · filed 2025-08-13 | $4.19M 10-Q · filed 2025-08-13 | $5.48M derived: sum of 3 quarters · filed 2026-05-13 | $7.74M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2025-03-31 | $2.14M 10-Q · filed 2026-05-13 | $3.43M derived: sum of 2 quarters · filed 2026-05-13 | $5.70M derived: sum of 3 quarters · filed 2026-05-13 | $8.45M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $3.56M derived: sum of 2 quarters · filed 2026-03-31 | $6.31M derived: sum of 3 quarters · filed 2026-03-31 | $9.14M 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $2.27M 10-Q · filed 2025-11-19 | $5.02M derived: sum of 2 quarters · filed 2025-11-19 | $7.85M 10-Q · filed 2025-11-19 | $21.78M derived: sum of 4 quarters · filed 2025-11-19 | ||
| 2024-06-30 | $2.75M 10-Q · filed 2025-08-13 | $5.58M 10-Q · filed 2025-08-13 | $19.52M derived: sum of 3 quarters · filed 2025-08-13 | $22.42M derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $2.83M 10-Q · filed 2025-05-12 | $16.76M derived: sum of 2 quarters · filed 2025-05-12 | $19.66M derived: sum of 3 quarters · filed 2025-05-12 | $105.99M derived: sum of 4 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $13.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $16.84M derived: sum of 2 quarters · filed 2025-03-27 | $103.16M derived: sum of 3 quarters · filed 2025-03-27 | $107.75M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $2.90M 10-Q · filed 2024-11-14 | $89.23M derived: sum of 2 quarters · filed 2024-11-14 | $93.82M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $86.33M 10-Q · filed 2024-08-09 | $90.92M 10-Q · filed 2024-08-09 | ||||
| 2023-03-31 | $4.59M 10-Q · filed 2024-05-15 | |||||
| 2022-12-31 | $820.07K 10-K · filed 2024-03-25 | |||||
| 2022-12-12 | $13.01M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |